A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 [sorafenib] single agent therapy in patients with operable renal cell cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2009
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 23 Sep 2009 Additional trial lead centres as reported by Netherlands Trial Register record.
- 23 Sep 2009 Status changed from completed to planning as reported by Netherlands Trial Register record.
- 22 Sep 2009 New source identified and integrated (Netherlands Trial Register).